Table 4.

Malignant glioma patients diagnosed with intracranial hemorrhages (ICH) while on antiangiogenic therapy

Patient	Age at diagnosis/ gender	Type of ICH	Tumor histology	Location of tumor	Risk factors for ICH	No. of prior anti- glioma regimens	Prior anti-VEGF/ VEGFR Regimens	Time on anti- VEGF/ VEGFR prior to ICH (mos.)	Time from tumor Diagnosis to ICH (mos.)	Regimen at time of Event	Symptoms at diagnosis of ICH	Survival after ICH (mos.)
1t	34/M	Intratumoral	Anaplastic  oligoastrocytoma	R frontal/  temporal	HTN	2	None	0.9	124.9	Bevacizumab,  enzastaurin	Asymptomatic	2.4+
2t	36/M	Intratumoral	Anaplastic  oligodendroglioma	Bilateral  temporal/  parietal/  occipital,  corpus  callosum	Anticoagulant use	6	None	2.2	50.8	Vandetanib	Hemiparesis,  AMS	1.5
3t	46/M	Intratumoral	Gliosarcoma	R frontal	None	4	Bevacizumab	1.3	14.7	Sunitinib	AMS,  Vomiting,  Headache	0.7
4t	50/M	Intratumoral	GBM	L frontal/parietal	None	2	None	0.9	11.3	Bevacizumab,  enzastaurin	Asymptomatic	2.6
5	51/M	Intratumoral	GBM	L temporal	None	1	None	2.6	16.2	Bevacizumab	Asymptomatic	1.5+
6	56/M	Intratumoral	AA	R temporal	None	5	Bevacizumab,  enzastaurin; Sunitinib,  Bevacizumab	4.4	35.0	Bevacizumab,  carboplatin	Seizure	1.7
7t	59/F	Intratumoral	AA	R frontal	Mild  thrombocytopenia	2	Bevacizumab,  enzastaurin	4.6	19.7	Sunitinib	Hemiparesis,  AMS	3.7
8t	62/M	Intratumoral	GBM	R frontal/  temporal	HTN	4	Bevacizumab,  temozolomide;  Bevacizumab,  irinotecan;  Bevacizumab,  carboplatin	12.7	18.8	Sunitinib	AMS	0.5
9t	67/M	Intratumoral	GBM	R temporal	HTN	1	None	9.0	18.9	Vandetinib	Asymptomatic	7.3
10	51/M	Intratumoral,  Subdural	Gliosarcoma	L frontal/parietal	HTN, Antiplatelet  use	1	None	15.9	21.2	Bevacizumab	Language  Changes,  AMS,  Vomiting,  Headache	2.9+
11	52/M	Intratumoral  Intraventricular	Anaplastic  oligoastrocytoma	Bilateral frontal,  corpus  callosum,  cerebellum  brainstem	Anticoagulant use	2	None	0.2	168.8	Bevacizumab,  irinotecan	AMS, Gait  Changes	1.3+
12t	60/M	Subdural	AA	Corpus callosum	None	1	None	10.0	18.6	Bevacizumab	AMS, Gait  Changes	4.6
13	37/M	Cavernoma  intralesional	GBM	L fronto-  parietal	None	1	None	0.8	96.8	Bevacizumab,  carboplatin	Asymptomatic	2.0+
14t	47/F	Unspecified  intracerebral	GBM	R parietal/  occipital	None	2	Bevacizumab	4.5	19.5	Vandetinib	Hemiparesis,  AMS	0.3

HTN hypertension, GBM glioblastoma, AA anaplastic astrocytoma, AMS altered mental status, t patients with ICH while on clinical trial